Multiple endocrine neoplasia syndrome type 2 (MEN2): Patients with MEN2 should not receive cagrilintide because of its receptor overlap with calcitonin pathways
Once the medication is available again, people often need to go back to the starting dose, even if they were on a high dose before
Kordonouri O, Hartmann R, Badenhoop K, Kahles H, Ilonen J
The FDA has been sending warning letters to the companies that are illegally supplying the peptide, said Tenille Davis, a pharmacist and chief advocacy officer for the trade group Alliance for Pharmacy Compounding
Easy Nutrition Guide to Lose Weight on Semaglutide A Patient-Ready Resource for Wegovy and Ozempic Users (Updated for 2026) Give your patients clear, practical nutrition guidance they can actually follow while on GLP-1 medications